Compugen reports third quarter revenue of $1.9 million and cash position of $86.1 million

Reuters

2025/11/10

Compugen reports third quarter revenue of $1.9 million and cash position of $86.1 million

Compugen Ltd. reported revenues of approximately $1.9 million for the third quarter ended September 30, 2025, a decrease from $17.1 million in the same period of 2024. Research and development expenses were $5.8 million, down from $6.3 million in the third quarter of 2024. General and administrative expenses were $2.2 million compared to $2.6 million in the previous year. The company reported a net loss of $7.0 million, or $0.07 per basic and diluted share, versus a net profit of $1.3 million, or $0.01 per basic and diluted share, in the third quarter of 2024. As of September 30, 2025, Compugen held $86.1 million in cash, cash equivalents, short-term bank deposits, and marketable securities, with no debt, and expects its cash position to fund operations into the third quarter of 2027. During October 2025, the company sold approximately 0.8 million shares through its ATM facility, raising about $1.6 million. Compugen continues to advance its immuno-oncology pipeline and maintains partnerships with AstraZeneca and Gilead.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Compugen Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: IO18568) on November 10, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2582887392"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2582887392\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2582887392?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-10 20:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582887392","market":"fut","top_or_hot":-1,"title":"Compugen reports third quarter revenue of $1.9 million and cash position of $86.1 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Compugen reports third quarter revenue of $1.9 million and cash position of $86.1 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Compugen Ltd. reported revenues of approximately $1.9 million for the third quarter ended September 30, 2025, a decrease from $17.1 million in the same period of 2024. Research and development expenses were $5.8 million, down from $6.3 million in the third quarter of 2024. General and administrative expenses were $2.2 million compared to $2.6 million in the previous year. The company reported a net loss of $7.0 million, or $0.07 per basic and diluted share, versus a net profit of $1.3 million, or $0.01 per basic and diluted share, in the third quarter of 2024. As of September 30, 2025, Compugen held $86.1 million in cash, cash equivalents, short-term bank deposits, and marketable securities, with no debt, and expects its cash position to fund operations into the third quarter of 2027. During October 2025, the company sold approximately 0.8 million shares through its ATM facility, raising about $1.6 million. Compugen continues to advance its immuno-oncology pipeline and maintains partnerships with AstraZeneca and <a href=\"https://laohu8.com/S/GILD\">Gilead</a>.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Compugen Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: IO18568) on November 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Compugen reports third quarter revenue of $1.9 million and cash position of $86.1 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCompugen reports third quarter revenue of $1.9 million and cash position of $86.1 million\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-11-10 20:03</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Compugen reports third quarter revenue of $1.9 million and cash position of $86.1 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Compugen Ltd. reported revenues of approximately $1.9 million for the third quarter ended September 30, 2025, a decrease from $17.1 million in the same period of 2024. Research and development expenses were $5.8 million, down from $6.3 million in the third quarter of 2024. General and administrative expenses were $2.2 million compared to $2.6 million in the previous year. The company reported a net loss of $7.0 million, or $0.07 per basic and diluted share, versus a net profit of $1.3 million, or $0.01 per basic and diluted share, in the third quarter of 2024. As of September 30, 2025, Compugen held $86.1 million in cash, cash equivalents, short-term bank deposits, and marketable securities, with no debt, and expects its cash position to fund operations into the third quarter of 2027. During October 2025, the company sold approximately 0.8 million shares through its ATM facility, raising about $1.6 million. Compugen continues to advance its immuno-oncology pipeline and maintains partnerships with AstraZeneca and <a href=\"https://laohu8.com/S/GILD\">Gilead</a>.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Compugen Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: IO18568) on November 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1153584641.USD","symbol_name":"BGF EUROPEAN EQUITY INCOME \"A2\" (USDHDG) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nNDLbptjNr:1","article_id":"2582887392","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582887392","pubTimestamp":1762776210,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Compugen Ltd. reported revenues of approximately $1.9 million for the third quarter ended September 30, 2025, a decrease from $17.1 million in the same period of 2024. Research and development expenses were $5.8 million, down from $6.3 million in the third quarter of 2024. General and administrative expenses were $2.2 million compared to $2.6 million in the previous year. The company reported a net loss of $7.0 million, or $0.07 per basic and diluted share, versus a net profit of $1.3 million, or $0.01 per basic and diluted share, in the third quarter of 2024. As of September 30, 2025, Compugen held $86.1 million in cash, cash equivalents, short-term bank deposits, and marketable securities, with no debt, and expects its cash position to fund operations into the third quarter of 2027. During October 2025, the company sold approximately 0.8 million shares through its ATM facility, raising about $1.6 million. Compugen continues to advance its immuno-oncology pipeline and maintains partne","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1153584641.USD":"BGF EUROPEAN EQUITY INCOME \"A2\" (USDHDG) ACC","IE00B7SZLL34.SGD":"Legg Mason ClearBridge - Value A Acc SGD-H","LU1481600234.SGD":"THREADNEEDLE (LUX) UK EQUITY INCOME \"ASC\" (SGDHDG) INC","LU0949170426.SGD":"Blackrock Global Multi-Asset Income A6 SGD-H","LU1019632923.USD":"Blackrock European Equity Income A6 USD-H","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","LU0889565080.SGD":"FTIF - Templeton European Opportunities A Acc SGD-H1","AZN.UK":"阿斯利康制药","LU0738911758.USD":"Blackrock Global Equity Income A6 USD","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","GILD":"吉利德科学","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","LU0784384876.USD":"Blackrock Global Multi-Asset Income A6 USD","LU1487256676.USD":"THREADNEEDLE (LUX) UK EQUITY INCOME \"ZUH\" (USDHDG) ACC","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","LU0784385840.USD":"Blackrock Global Multi-Asset Income A2 USD","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU2091194634.USD":"BGF EUROPEAN EQUITY INCOME \"A2\" (USD) ACC","LU1019634622.SGD":"Blackrock European Equity Income A6 SGD-H","03165":"华夏欧优股对冲","LU0058720904.USD":"联博国际健康护理基金A","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","CGEN":"Compugen医疗","LU1880407215.USD":"AMUNDI FUNDS NET ZERO AMBITION TOP EUROPEAN PLAYERS \"A2\" (USD) INC","SG9999015986.USD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (USD) ACC","LU0077335932.USD":"FIDELITY AMERICAN GROWTH \"A\" INC","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1496350171.SGD":"FRANKLIN DIVERSIFIED BALANCED \"A\" (SGDHDG) ACC","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU2114397693.USD":"BGF EUROPEAN EQUITY INCOME \"A\" (USDHDG) INC","LU1496350502.SGD":"FRANKLIN DIVERSIFIED DYNAMIC \"A\" (SGDHDG) ACC","LU1267930573.SGD":"TEMPLETON GLOBAL \"AA\" (SGD) ACC A","LU0345777147.USD":"NINETY ONE GSF EUROPEAN EQUITY \"A\" (USD) ACC","LU1814569148.SGD":"WELLINGTON GLOBAL QUALITY GROWTH \"D\" (SGDHDG) ACC","LU0047473722.EUR":"HSBC GIF EUROPE VALUE \"PD\" (EUR) INC","LU0757432116.USD":"THREADNEEDLE (LUX) PAN EUROPEAN ESG EQUITIES \"AE\" (USD) ACC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU1674673691.USD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AD\" (USD) INC","LU0889566641.SGD":"FTSF - Templeton Shariah Global Equity A Acc SGD","LU0432979614.USD":"JPM GLOBAL HEALTHCARE \"A\" ACC","LU0553294199.USD":"BGF GLOBAL EQUITY INCOME \"A5G\" (USD) INC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","BK4532":"文艺复兴科技持仓","LU1839511570.USD":"WELLS FARGO GLOBAL FACTOR ENHANCED EQUITY \"I\" (USD) ACC","LU1119994496.HKD":"FIDELITY WORLD \"A\" (HKD) ACC","LU1267930813.SGD":"FRANKLIN TEMPLETON SHARIAH GLOBAL EQUITY \"AS\" (SGD) ACC","LU0708994859.HKD":"TEMPLETON GLOBAL \"A\" (HKD) ACC","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD"},"translate_title":"Compugen报告第三季度收入为190万美元，现金状况为8610万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AZN.UK":0.9,"03165":0.6,"CGEN":0.9,"GILD":0.9},"content_text":"Compugen reports third quarter revenue of $1.9 million and cash position of $86.1 million\n    \n\n        Compugen Ltd. reported revenues of approximately $1.9 million for the third quarter ended September 30, 2025, a decrease from $17.1 million in the same period of 2024. Research and development expenses were $5.8 million, down from $6.3 million in the third quarter of 2024. General and administrative expenses were $2.2 million compared to $2.6 million in the previous year. The company reported a net loss of $7.0 million, or $0.07 per basic and diluted share, versus a net profit of $1.3 million, or $0.01 per basic and diluted share, in the third quarter of 2024. As of September 30, 2025, Compugen held $86.1 million in cash, cash equivalents, short-term bank deposits, and marketable securities, with no debt, and expects its cash position to fund operations into the third quarter of 2027. During October 2025, the company sold approximately 0.8 million shares through its ATM facility, raising about $1.6 million. Compugen continues to advance its immuno-oncology pipeline and maintains partnerships with AstraZeneca and Gilead.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Compugen Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: IO18568) on November 10, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}